MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease
ConditionLiver Diseases
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Chicago
About this trial
The purpose of the study is to study the muscle assessment score (MAsS, utilizing MRI, as an objective measure of frailty and muscle composition to serve as a predictor of morbidity and mortality in patients with liver disease.
Eligibility criteria
Qualifiers
Patients who are already scheduled for an MRI for routine clinical purposes will be evaluated
Disqualifiers
<18 yrs. of age
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Locations
1The University of Chicago60637, ChicagoIllinois, United States
Sponsors and collaborators
University of Chicago
Lead sponsor
Source ClinicalTrials.gov